Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Summary on Apr 16, 2018

April 16, 2018 - By Julie Barnes

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Total analysts of 4 have positions in Celldex (NASDAQ:CLDX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 50%. Since November 7, 2017 according to StockzIntelligence Inc Celldex has 4 analyst reports. On Thursday, March 8 the firm earned “Hold” rating by Jefferies. On Tuesday, November 7 the firm has “Buy” rating given by H.C. Wainwright. In Wednesday, December 6 report WBB Securities maintained the stock with “Buy” rating. In Thursday, March 8 report Leerink Swann maintained it with “Market Perform” rating and $3 target. Listed here are Celldex Therapeutics, Inc. (NASDAQ:CLDX) PTs and latest ratings.

08/03/2018 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $4 New Target: $3 Maintain
06/12/2017 Broker: WBB Securities Rating: Buy New Target: $10.0 Maintain
07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain

CLDX reached $0.8916 on during the last trading session after $1.2584 change.Celldex Therapeutics, Inc. has 13.10 million shares volume, 826.56% up from normal. CLDX is downtrending and has moved 30.36% since April 16, 2017. CLDX underperformed the S&P 500 by 41.91%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The company has $125.78 million market cap. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Last it reported negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: